BiotechTube

SC262

Phase 1Active
0 watching 0 views this week๐Ÿ’ค Quiet
28
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non Hodgkin's Lymphoma

Conditions

Non Hodgkin's Lymphoma, Large B-cell Lymphoma

Trial Timeline

Apr 18, 2024 โ†’ Mar 1, 2029

NCT ID
NCT06285422

About SC262

SC262 is a phase 1 stage product being developed by Sana Biotechnology for Non Hodgkin's Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT06285422. Target conditions include Non Hodgkin's Lymphoma, Large B-cell Lymphoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06285422Phase 1Active

Competing Products

20 competing products in Non Hodgkin's Lymphoma

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
52
TazemetostatEisaiPhase 2
52
ONTAKEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
Nivolumab + Brentuximab vedotinOno PharmaceuticalPhase 3
77
R-mabHDI and ABVD + ABVDEli LillyPhase 3
77
Prednisone + Vinblastine + Doxorubicin (Adriamycin) + GemcitabineEli LillyPhase 1/2
41
gemcitabineEli LillyPhase 2
52
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
52
R-mabHD + ABVDEli LillyPhase 2
52
LY317615Eli LillyPhase 2
52
LY4584180 + RituximabEli LillyPhase 1
33
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
77
HRS-3738Jiangsu Hengrui MedicinePhase 1
33
SHR1459 ๏ผ›YY-20394 + SHR1459 ๏ผ›YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
52
ABT-199 + KetoconazoleAbbViePhase 1
33
ABT-199 + RifampinAbbViePhase 1
33
[14C]ABT-199 (GDC-0199)AbbViePhase 1
33

Other Products from Sana Biotechnology

SC291Phase 1
28
SC291Phase 1
28
UP421Phase 1
28